^
Association details:
| Biomarker: | CXCR4 mutation |
|---|---|
| Cancer: | Waldenstrom Macroglobulinemia |
| Drug: | Brukinsa (zanubrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ASPEN: Long-Term Follow-up Results of a Phase 3 Randomized Trial of Zanubrutinib (ZANU) vs Ibrutinib (IBR) in Patients (PTS) with Waldenström Macroglobulinemia (WM)
Published date:
07/22/2022
Excerpt:
ASPEN is an open‑label, multicenter, randomized phase 3 study of zanubrutinib vs ibrutinib in patients with WM….CXCR4 mutation status was assessed retrospectively by NGS using residual DNA samples or duplicate bone marrow biopsy sample….In patients with CXCR4MUT confirmed by NGS, zanubrutinib demonstrated deeper and faster responses, as well as favorable PFS, compared with ibrutinib (Figure 5 and Table 2).
Trial ID:
Source:
Title:
The Efficacy and Safety of Zanubrutinib, Dexamethasone and or Not Cyclophosphamide Regimen in Symptomatic Waldenstrom Macroglobulinnemia
Published date:
11/02/2023
Excerpt:
A total of 30 Patients with WM were enrolled in this study median age 67(36-89); 76.7% males, 15 patients were untreated, others were treated patients. IPSS assessment grade1 26.7%; grade2 16.7%; grade3 56.6%. 80.0% (24/30) patients with MYD88L265P mutation 17.6% (3/17) patients with CXCR4 mutation...95%of patients were progression-free at 6 months in 25 evaluable patients. ORR was 95% in those (24/25) received ZD/ZCD regimen more than 2 months...These results demonstrate that zanubrutinib, dexamethasone and or not cyclophosphamide are quickly effective in the treatment of WM, with more deeper response...
Secondary therapy:
cyclophosphamide;
DOI:
10.1182/blood-2023-189130
